Hikma Pharmaceuticals USA Inc. agreed to acquire Naloxone And Epinephrine Nasal Sprays from INSYS Therapeutics, Inc. (OTCPK:INSY.Q) for $17 million on August 5, 2019. The Asset Purchase Agreement is subject to approval by the Bankruptcy Court and provides for customary closing conditions, including entry and effectiveness of the sale order of the Bankruptcy Court authorizing and approving the transaction, and delivery of certain transfer letters to the U.S. Food and Drug Administration related to the products being sold. The Asset Purchase Agreement also provides for customary termination rights. On August 22, 2019, the Bankruptcy Court entered an order approving the Hikma purchase agreement. Frederick S. Green, Gary T. Holtzer, Brenda L. Funk and Ronit Berkovich of Weil, Gotshal & Manges LLP acted as legal advisor for INSYS Therapeutics, Inc. Lazard Ltd (NYSE:LAZ) acted as the financial advisor to INSYS Therapeutics, Inc. The transaction was jointly administered by John Henry Knight, Zachary I. Shapiro and Paul N. Heath of Richards, Layton & Finger, P.A. Hikma Pharmaceuticals USA Inc. completed the acquisition of Naloxone And Epinephrine Nasal Sprays from INSYS Therapeutics, Inc. (OTCPK:INSY.Q) on August 29, 2019.